Showing 2801-2810 of 5771 results for "".
- Ashvattha Therapeutics Presents Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Diseasehttps://modernod.com/news/ashvattha-therapeutics-present-positive-phase-2-results-for-subcutaneous-migaldendranib-in-retinal-vascular-disease-at-arvo/2482795/Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib (MGB), a novel subcutaneously administered nanomedicine treatment for retinal vascular diseases. Updated results were presented in a poster session at the
- Topcon Healthcare Launches IDHea to Fuel AI and Digital Health Innovation from the Eyehttps://modernod.com/news/topcon-healthcare-launches-idhea-to-fuel-ai-and-digital-health-innovation-from-the-eye/2482792/Topcon Healthcare announced the launch of the Institute of Digital Health (IDHea), an ocular data-as-a-service platform designed to accelerate AI research and digital health innovation. IDHea is designed to provide fast and secure access to unique real-world and clinical trial datasets,
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2025 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2025-conference/2482791/The Neuro-Optometric Rehabilitation Association, International (NORA), which advocates for advancing neurovisual rehabilitation, has opened registration for its 35th Annual Conference, taking place September 18–21, 2025, at the Hilton Denver City Center in Denver, Colorado. N
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Aldeyra Plans to Resubmit NDA for DED Candidate Reproxalap After Dry Eye Chamber Trial Resultshttps://modernod.com/news/aldeyra-plans-to-resubmit-nda-for-ded-candidate-reproxilap-after-dry-eye-chamber-trial-results/2482788/Aldeyra Therapeutics announced it has achieved the primary endpoint in a phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of its investigational drug candidate reproxalap.
- Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Partner to Launch New Medical Technology Companyhttps://modernod.com/news/moorfields-eye-hospital-ucl-institute-of-ophthalmology-and-topcon-partner-to-launch-new-medical-technology-company/2482786/Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Healthcare announced the launch of Cascader Limited, a new medical technology company that aims to transform the detection and management of eye disease through artificial intelligence (AI). Cascade
- Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveohttps://modernod.com/news/iantrek-hits-2000-procedures-for-new-bio-interventional-technology-alloflo-uveo/2482785/Iantrek announced it has surpassed 2,000 AlloFlo Uveo procedures in the US. The key milestone comes ahead of its full commercial launch planned for this fall during the American Academy of Ophthalmology 2025 meeting. Recent momentum has been fueled by the publication of 2-year
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Alcon Offers Eye Care Innovators a Shot at $1M Seed Investmenthttps://modernod.com/news/alcon-offers-eye-care-innovators-a-shot-at-1m-seed-investment/2482779/Alcon announced a collaboration with the Association for Research in Vision and Ophthalmology (ARVO) to support its live